Table 3

(A) Toxicities observed during induction ipilimumab/nivolumab in metastatic UM

ToxicityGradeTotal (%)
(A)G1 (%)G2 (%)G3 (%)G4 (%)Unknown (%)
Diarrhea/colitis5 (5.6)4 (4.5)10 (11.2)1 (1.1)8 (9.0)28 (31.5)
Fatigue8 (9.0)4 (4.5)1 (1.1)0 (0.0)7 (7.9)20 (22.5)
Hypoadrenalism0 (0.0)1 (1.1)2 (2.2)0 (0.0)2 (2.2)5 (5.6)
Hypophysitis0 (0.0)1 (1.1)3 (3.4)0 (0.0)5 (5.6)9 (10.1)
Hypothyroid1 (1.1)9 (10.1)0 (0.0)0 (0.0)7 (7.9)17 (19.1)
Pneumonitis0 (0.0)2 (2.2)2 (2.2)0 (0.0)2 (2.2)6 (6.7)
Rash8 (9.0)3 (3.4)3 (3.4)0 (0.0)5 (5.6)19 (21.3)
Transaminitis4 (4.5)3 (3.4)5 (5.6)1 (1.1)6 (6.7)19 (21.3)